UNSPSC 51385604: Detanosal

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y09NU9DS9B, chemically known as salicylic acid, 2-(diethylamino)ethyl ester but generally known as detanosal, which bears US NIH Compound Identifier 160413. European Medicines Agency schedules Detanosal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07009MIG. The term DETANOSAL is an International Non-Proprietary Name.

UNSPSC 51385604 Detanosal is a Commodity-level code that encompasses opioid-antagonist medications and related emergency pharmaceutical supplies procured by state and local health departments, county emergency services, and multistate cooperative purchasing alliances to support community health initiatives, overdose response programs, and pharmacy benefit management. The code captures naloxone products, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products supplied through authorized wholesale channels and directly from manufacturers. State and local issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of multiple state and local government facilities including Oregon).

Recent activity spans Florida, Texas, and the multistate MMCAP region. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at establishing direct relationships between the state pharmacy benefit program and pharmaceutical manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations emphasize compliance with federal manufacturing and supply-chain security standards, including cGMP and DSCSA certification, and require vendors to maintain specified insurance coverage.